Abstract Library

#3987 m6A modifications promote the invasion and metastasis of pancreatic neuroendocrine neoplasms by activating the Integrin/FAK signalling pathway via TGFBI

Introduction: Nearly 50% of patients with pNENs have metastases at the time of initial diagnosis, and there is a lack of effective treatment once they have metastases. The 5-year overall survival rate for G3 pNENs with metastasis at diagnosis was 0, which was significantly lower than that for patients without metastasis, with a 5-year overall survival rate of 43%. At present, the pathogenesis of pNENs has not been clarified.

Conference:

Presenting Author:

Authors: Ye M, Tang Q,

Keywords: RNA methyltransferases, Tumor metastasis, Pancreatic neuroendocrine neoplasm, Transforming growth factor-β-induced gene, Integrin/FAK signaling pathway,

#3512 Genetic, epigenetic and/or transcriptional profiling of 14q genes, MAX and MEG3 in pituitary neuroendocrine tumors

Introduction: Recent studies have identified a growing series of susceptibility genes for pituitary neuroendocrine tumors (PitNETs) and pheochromocytomas/paragangliomas (PPGL). Some of these genes (e.g., SDH genes) have be specifically associated with the development of these pathologies.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, Letón R, Rivero-Cortés E, Álvarez-Escolá C, Rodriguez Poyo-Guerrero P,

Keywords: pituitary tumor, epigenetics, MAX, genomics,

#3241 Clinical features and management of paragangliomas in a tertiary university hospital

Introduction: Paragangliomas (PG) are rare neuroendocrine tumors that arise from the extra-adrenal paraganglia. The most frequent location is head and neck PG (HNPG), usually non-functioning tumors. PG present a high rate of genetic susceptibility mainly associated with SDHx mutation. Clinical presentation depends upon catecholamine secretion and tumor location. Surgery remains the standard treatment, although radiotherapy and systemic therapies can be considered for unresectable or metastatic disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Damaso S, Lopes Brás R, Paiva R, Macedo D, Fernandes I,

Keywords: paraganglioma, treatment, sdhb gene,

#1478 The Role of p27 in Pheochromocytoma Development

Introduction: The Cdkn1b gene, encoding p27, is a tumor susceptibility gene for multiple endocrine neoplasia syndromes in rats (MENX) and humans (MEN4) with development of pheochromocytoma (PCC), respectively. Recently, it was reported that p27 indirectly regulates gene transcription by associating with transcription factors (TF) and inhibiting gene transcription at specific promoters.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Richter A

Authors: Richter A, Lalli E, Sass S, Pellegata N,

Keywords: pheochromocytoma, p27, ChIP-Seq,

#1100 Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Canzian F

Authors: Campa D, Rizzato C, Capurso G, Delle Fave G, Gazouli M,

Keywords: pancreatic neuroendocrine tumor, p16, cdkn2a, genetic polymorphisms, SNP, association, susceptibility,